Meridian Bioscience NAAT for Group A Strep Shines in Multicenter Clinical Study | GenomeWeb

Meridian Bioscience's Illumigene nucleic acid amplification test for Streptococcus pyogenes, or Group A Streptococcus, has a clinical sensitivity of 99 percent and specificity of 99.6 percent when compared to the diagnostic gold standard of culture and discrepant analysis using another nucleic acid amplification test, according to a study published last week in the Journal of Clinical Microbiology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Three researchers win the Nobel Prize for their efforts to develop treatments for parasitic diseases.

In PLOS this week: effect of variants linked to body shape differs by age and sex, transcriptome differences in bats with and without white-nose syndrome, and more.

A researcher argues that big prizes like the Nobel or Lasker awards send the wrong message about research.

Maria Freire, the president of the Foundation for the National Institutes of Health, discusses recent genomics-fueled advances with The Open Mind's Alexander Heffner.